Analysis of @entity983 , @entity817 , and @entity470 status in determining benefit from cetuximab therapy in wild-type XXXX metastatic colon cancer.

@entity1 @entity984 @entity5 @entity470 @entity983 @entity14 @entity817 @entity1349
PURPOSE: The occurrence of @entity984 mutation is predictive of nonresponse and shorter survival in @entity1 treated by anti- @entity470 (anti- @entity470 ) antibody for metastatic @entity14 (mCRC), leading the European Medicine Agency to limit its use to @entity1 with wild-type @entity984 @entity5 . However, only half of these @entity1 will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy. @entity1 AND METHODS: We retrospectively collected @entity5 from 173 @entity1 with mCRC. All but one @entity1 received a cetuximab-based regimen as second-line or greater therapy. @entity984 and @entity817 status were assessed by allelic discrimination. @entity470 amplification was assessed by chromogenic in situ hybridization and fluorescent in situ hybridization, and the expression of @entity983 was assessed by immunochemistry. RESULTS: In @entity1 with @entity984 wild-type @entity5 (n = 116), @entity817 mutations (n = 5) were weakly associated with lack of response (P = .063) but were strongly associated with shorter progression-free survival (P < .001) and shorter @entity1349 ( @entity1349 ; P < .001). A high @entity470 polysomy or an @entity470 amplification was found in 17.7% of the @entity1 and was associated with response (P = .015). @entity983 null expression was found in 19.9% of the @entity1 and was associated with shorter @entity1349 (P = .013). In multivariate analysis, @entity817 mutation and @entity983 expression status were associated with @entity1349 . CONCLUSION: @entity817 status, @entity470 amplification, and cytoplasmic expression of @entity983 were associated with outcome measures in @entity984 wild-type @entity1 treated with a cetuximab-based regimen. Subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.
